Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from GlaxoSmithKline ( (GB:GSK) ).
GSK has announced a settlement with CureVac and BioNTech regarding mRNA patent litigation, resulting in a $370 million upfront payment and a 1% royalty on future US sales of mRNA vaccines by Pfizer and BioNTech. This settlement, which will be recorded in GSK’s financial results, does not affect GSK’s ongoing patent enforcement against Pfizer and BioNTech in the US and Europe, and includes a tender agreement for GSK’s CureVac shares.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.
GlaxoSmithKline’s overall stock score reflects strong financial performance and strategic initiatives, such as share buybacks and acquisitions, which enhance shareholder value. The technical indicators suggest a neutral market sentiment, while the valuation is fair with an attractive dividend yield. The earnings call highlights growth in specialty medicines, though challenges in vaccine sales and regulatory impacts are noted.
To see Spark’s full report on GB:GSK stock, click here.
More about GlaxoSmithKline
GSK is a global biopharmaceutical company focused on leveraging science, technology, and talent to advance healthcare and combat diseases.
Average Trading Volume: 9,063,325
Technical Sentiment Signal: Sell
Current Market Cap: £56.36B
Learn more about GSK stock on TipRanks’ Stock Analysis page.